2-[N-甲基-N-(2-吡啶基)氨基]乙醇 | 122321-04-4

• 物质功能分类: 医药中间体 - 杂环化合物 - 吡啶类化合物
• 分子结构分类: 有机化合物 - 有机氮化合物
• 中文名称: 2-[N-甲基-N-(2-吡啶基)氨基]乙醇
• 中文别名: 2-(N-甲基-2-吡啶氨基)乙醇；N-甲基-N-(2-吡啶基)氨基乙醇；N-甲基-2-(哌啶-4-基氧)氨基乙醇；2-[(N-甲基-N-2-吡啶基)胺基]乙醇；2-N-甲基-2-吡啶氨基乙醇；2-[(N-甲基-N-2-吡啶基) 胺基]乙醇
• 英文名称: 2-(N-methyl-N-(pyridin-2-yl)amino)ethanol
• 英文别名: 2-(methyl(pyridin-2-yl)amino)ethanol；2-(methyl(pyridin-2-yl)amino)ethan-1-ol；2-(methyl-2-pyridylamino)ethanol；2-[N-methyl-N-(2-pyridyl)]aminoethanol；2-[N-(2-hydroxyethyl)-N-methylamino]pyridine；2-[methyl(pyridin-2-yl)amino]ethanol
• CAS: 122321-04-4
• 化学式: C₈H₁₂N₂O
• mdl: MFCD02667633
• 分子量: 152.196
• InChiKey: MWGKOPUDDQZERY-UHFFFAOYSA-N

物化性质

• 沸点：
  98-100°C 0,1mm
• 密度：
  1.12
• 稳定性/保质期：
  如果按照规格使用和储存，则不会分解，且没有已知的危险反应。请避免与氧化物接触。

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  11
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.375
• 拓扑面积：
  36.4
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xn
• 危险类别码：
  R22,R36/37/38
• 海关编码：
  2933399090
• 危险类别：
  IRRITANT
• 安全说明：
  S26,S37/39
• 储存条件：
  请将贮藏器保持密封，并存放在阴凉、干燥处。确保工作间有良好的通风或排气装置。

SDS

Name:	2-N-methyl-2-pyridylaminoethanol Material Safety Data Sheet
Synonym:
CAS:	122321-04-4

Section 1 - Chemical Product MSDS Name:2-N-methyl-2-pyridylaminoethanol Material Safety Data Sheet
Synonym:

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
122321-04-4	2-N-Methyl-2-pyridylaminoethanol		unlisted

Hazard Symbols: XN
Risk Phrases: 22 36/37/38

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Harmful if swallowed. Irritating to eyes, respiratory system and skin.
Potential Health Effects
Eye:
Causes eye irritation.
Skin:
Causes skin irritation. May be harmful if absorbed through the skin.
Ingestion:
Harmful if swallowed. May cause irritation of the digestive tract.
Inhalation:
Causes respiratory tract irritation. May be harmful if inhaled.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Absorb spill with inert material (e.g. vermiculite, sand or earth), then place in suitable container.

---

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 122321-04-4: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Liquid
Color: faint yellow - light yellow to light brown
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: Not available.
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C8H12N2O
Molecular Weight: 152.2

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Strong oxidizing agents, strong bases.
Hazardous Decomposition Products:
Nitrogen oxides, carbon monoxide, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 122321-04-4 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
2-N-Methyl-2-pyridylaminoethanol - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Not regulated as a hazardous material.
IMO
Not regulated as a hazardous material.
RID/ADR
Not regulated as a hazardous material.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XN
Risk Phrases:
R 22 Harmful if swallowed.
R 36/37/38 Irritating to eyes, respiratory system
and skin.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 37/39 Wear suitable gloves and eye/face
protection.
WGK (Water Danger/Protection)
CAS# 122321-04-4: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 122321-04-4 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 122321-04-4 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

用途：用作药物罗格列酮的中间体。

反应信息

• 作为反应物：
  描述：

  2-[N-甲基-N-(2-吡啶基)氨基]乙醇 在 哌啶 、 sodium tetrahydroborate 、 cobalt(II) chloride hexahydrate 、 sodium hydride 、 二甲基乙二醛肟 、 sodium hydroxide 作用下， 以 水 、 N,N-二甲基甲酰胺 、 甲苯 为溶剂， 反应 54.0h， 生成 罗格列酮
  参考文献：
  名称：

  Synthetic optimization of rosiglitazone and related intermediates for industrial purposes

  摘要：

  作为一种重要的、新近获得美国食品药品监督管理局(FDA)批准的糖尿病治疗药物，罗格列酮(1)受到了众多领域研究人员的广泛关注。为寻找一种经济便捷的合成罗格列酮的方法，我们采用正交方法探究了五步可扩展合成路线的反应条件和后处理工艺，以确定每一步反应的最佳条件。起始原料均为市售品，包括2-氯吡啶(2)、N-甲基乙醇胺(3)、4-氟苯甲醛(4a)或4-羟基苯甲醛(4b)以及1,3-噻唑烷-2,4-二酮(5)。该五步连续反应分别为环化、烷基化、醚化、缩合和还原，其最佳产率分别为90%、99%、59%、75%和91%。基于化合物2合成罗格列酮的最佳整体产率为40%，适合工业化生产，以水为绿色溶剂，在最后三步反应中避免使用柱层析。

  DOI：

  10.1007/s11164-015-2132-0
• 作为产物：
  描述：

  2-氯吡啶 、 N-甲基-2-羟基乙胺 生成 2-[N-甲基-N-(2-吡啶基)氨基]乙醇
  参考文献：
  名称：

  具有2个取代的亚氨基3个取代的5-亚杂芳基-1,3-噻唑烷4-1骨架的新型强效PTP1B抑制剂的设计与合成：第一部分

  摘要：

  本文设计并合成了一系列新的2-取代的亚氨基-3-取代的5-亚杂亚基-1,3-噻唑烷-4-酮类作为有效的双齿PTP1B抑制剂。通过光谱分析对所有新化合物进行了表征和鉴定。对PTP1B的生物学筛选测试表明，其中一些化合物对PTP1B具有正抑制活性。具有5-取代的吡咯的化合物对1，3-噻唑烷-4-one的5-位的活性比那些具有5-取代的吡啶基的化合物的活性更强。化合物14b，14h和14i显示IC 50相对于PTP1B的数值分别为8.66μM，6.83μM和6.09μM。这些活性化合物与PTP1B的对接分析显示了这些双杂环化合物与PTP1B活性位点的可能相互作用方式。还对这组化合物进行了针对癌基因CDC25B的抑制试验，以评估其选择性和可能的​​抗肿瘤活性。在所有可能的抑制剂（包括14g，14h，14i和15c）中，化合物14b对CDC25B的IC 50最低，为1.66μM。计算了所有化合物的一

  DOI：

  10.1016/j.ejmech.2016.05.060
• 作为试剂：
  描述：

  (Z)-5-(4-氟亚苄基)噻唑烷-2,4-二酮 、 2-[N-甲基-N-(2-吡啶基)氨基]乙醇 在 2-[N-甲基-N-(2-吡啶基)氨基]乙醇 作用下， 以80的产率得到罗格列酮相关物质A
  参考文献：
  名称：

  Bioorg. Med. Chem. Lett. 2012, 22, 924-928

  摘要：

  DOI：

文献信息

• [EN] PYRROLOPYRIMIDINES<br/>[FR] PYRROLOPYRIMIDINES
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2009016132A1

  公开（公告）日：2009-02-05

  The present invention relates to compounds or pharmaceutically-acceptable salts thereof, processes for preparing them, pharmaceutical compositions containing them and their use in therapy. The invention particularly relates to compounds that are polo-like kinase (PLKs) inhibitors useful for the treatment of disease states mediated by PLK, especially PLK4, in particular such compounds that are useful in the treatment of pathological processes which involve an aberrant cellular proliferation, such as tumour growth, rheumatoid arthritis, restenosis and atherosclerosis.

  本发明涉及化合物或其药用盐，制备它们的方法，含有它们的药物组合物以及它们在治疗中的用途。该发明特别涉及一类极化样激酶（PLKs）抑制剂化合物，用于治疗由PLK介导的疾病状态，特别是PLK4，特别是在治疗涉及异常细胞增殖的病理过程中有用的化合物，如肿瘤生长、类风湿性关节炎、再狭窄和动脉粥样硬化。
• Organocatalytic Cyclization of COS and Propargylic Derivatives to Value‐Added Heterocyclic Compounds
  作者：Hui Zhou、Rui Zhang、Sen Mu、Hui Zhang、Xiao‐Bing Lu

  DOI：10.1002/cctc.201900490

  日期：2019.12.5

  and 1,3‐thiazolidine‐2,4‐diones derivatives in a highly chemo‐ and stereoselective manner. The isotope labeling and stoichiometric experiments suggested the LB‐COS adducts preferentially mediated basic ionic pair mechanism. Furthermore, the practical application of this methodology was highlighted by the highly efficient synthesis of rosiglitazone using COS as sulfur source.

  首先通过使用路易斯碱（LB）的COS加合物作为有机催化剂，将羰基硫化物（COS）进行炔丙基胺/酰胺的有机催化环化反应，从而提供各种功能化的1,3-噻唑烷-2-酮和1,3-噻唑烷- 2,4-二酮衍生物具有高度的化学和立体选择性。同位素标记和化学计量学实验表明LB-COS加合物优先介导基本离子对机理。此外，使用COS作为硫源高效合成罗格列酮，突显了该方法的实际应用。
• [EN] COMBINATIONS OF HEPATITIS C VIRUS INHIBITORS<br/>[FR] ASSOCIATIONS D'INHIBITEURS DU VIRUS DE L'HÉPATITE C
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2015005901A1

  公开（公告）日：2015-01-15

  The present disclosure is generally directed to antiviral compounds, and more specifically directed to combinations of compounds which can inhibit the function of the NS5A protein encoded by Hepatitis C virus (HCV), compositions comprising such combinations, and methods for inhibiting the function of the NS5A protein.

  本公开涉及抗病毒化合物，更具体地涉及能够抑制由丙型肝炎病毒（HCV）编码的NS5A蛋白功能的化合物组合，包括这种组合的组合物，以及抑制NS5A蛋白功能的方法。
• Sulfonamide compounds and medicinal use thereof
  申请人：Fujisawa Pharmaceutical Co., Ltd.

  公开号：US06348474B1

  公开（公告）日：2002-02-19

  A sulfonamide compound of the formula (I): R1—SO2NHCO—A—R2  (I) wherein R1 is alkyl, alkenyl, alkynyl and the like; A is an optionally substituted heteropolycyclic group except benzimidazolyl, indolyl, 4,7-dihydrobenzimidazolyl and 2,3-dihydrobenzoxazinyl; X is alkylene, oxa, oxa(lower)alkylene and the like; and R2 is optionally substituted aryl, substituted biphenylyl and the like, a salt thereof and a pharmaceutical composition comprising the same. The sulfonamide compound is effective for the diseases treatable based on their blood sugar level-depressing activity, cGMP-PDE (especially PDE-V)-inhibiting activity, smooth muscle relaxing activity, bronchodilating activity, vasodilating activity, smooth muscle cell suppressing activity, and antiallergic activity.

  化合物的化学式（I）为磺胺类化合物： R1—SO2NHCO—A—R2  （I） 其中R1为烷基，烯基，炔基等；A为除苯并咪唑基，吲哚基，4,7-二氢苯并咪唑基和2,3-二氢苯并噁嗪基之外的可选择取代的杂多环基团；X为烷基，氧杂环烷基等；R2为可选择取代的芳基，取代的联苯基等，其盐及包含其的药物组合物。该磺胺类化合物对于基于其降低血糖水平活性、cGMP-PDE（特别是PDE-V）抑制活性、平滑肌松弛活性、支气管扩张活性、血管扩张活性、平滑肌细胞抑制活性和抗过敏活性可治疗的疾病有效。
• Facile aromatic nucleophilic substitution (S_NAr) reactions in ionic liquids: an electrophile–nucleophile dual activation by [Omim]Br for the reaction
  作者：Xiao Zhang、Guo-ping Lu、Chun Cai

  DOI：10.1039/c6gc01742h

  日期：——

  A facile aromatic nucleophilic substitution reaction (SNAr) in recyclable [Omim]Br under relatively mild conditions has been described. An electrophile-nucleophile dual activation by [Omim]Br is also discovered based on control experiments,...

  已经描述了在相对温和的条件下在可再循环的[Omim] Br中的容易的芳族亲核取代反应（SNAr）。基于对照实验，还发现了[Omim] Br引起的亲电亲核双重激活，...